Tubidy

    Johnetta Blakely, MD, reflects on the progress and innovation of community oncologists

    02:18 •
    Johnetta Blakely, MD, reflects on the progress and innovation of community oncologists
    Download MP3

    Related Videos

    Charles Rudin, MD, PhD, shares the take home message regarding Keynote-604 for lung cancer treatment

    Charles Rudin, MD, PhD, shares the take home message regarding Keynote-604 for lung cancer treatment

    Sibel Blau, MD, tells us more about IQ Oncology

    Sibel Blau, MD, tells us more about IQ Oncology

    Jeff Vacirca, MD, discusses the capabilities of OneOncology's IT system

    Jeff Vacirca, MD, discusses the capabilities of OneOncology's IT system

    Kim N. Chi, MD, on what findings from the Phase III TITAN study mean for patients

    Kim N. Chi, MD, on what findings from the Phase III TITAN study mean for patients

    Alti Rahman, MHA\MBA, CSSBB, offers advice to oncology practices in today's cancer care landscape

    Alti Rahman, MHA\MBA, CSSBB, offers advice to oncology practices in today's cancer care landscape

    Madelyn Trupkin Herzfeld explains what does Carevive does to help patients with cancer

    Madelyn Trupkin Herzfeld explains what does Carevive does to help patients with cancer

    Hani Babiker, MD, describes the setting of FDA approval on tumor treatment fields

    Hani Babiker, MD, describes the setting of FDA approval on tumor treatment fields

    William Harwin, MD, tells us about the ancillary services his pracdtice has to help patients

    William Harwin, MD, tells us about the ancillary services his pracdtice has to help patients

    Banu Arun, MD, regarding the optimal setting for PARP inhibitors in breast cancer treatment

    Banu Arun, MD, regarding the optimal setting for PARP inhibitors in breast cancer treatment

    Sibel Blau, MD, speculates on the role of telehealth in cancer management

    Sibel Blau, MD, speculates on the role of telehealth in cancer management

    Banu Arun, MD, on PARP inhibitors in BRCA positive metastatic breast cancer

    Banu Arun, MD, on PARP inhibitors in BRCA positive metastatic breast cancer

    Stephen Grubbs, MD, discusses how we measure quality cancer care today

    Stephen Grubbs, MD, discusses how we measure quality cancer care today

    Deborah Korenstein, MD, on the benefits & harm of overuse of health services in cancer care

    Deborah Korenstein, MD, on the benefits & harm of overuse of health services in cancer care

    Joyce O’Shaughnessy, MD, on differentiating CDK4/6 inhibitors

    Joyce O’Shaughnessy, MD, on differentiating CDK4/6 inhibitors

    Michael Diaz, MD, on how community oncology is shaping the future of cancer care

    Michael Diaz, MD, on how community oncology is shaping the future of cancer care

    Debra Patt MD, expounds on the improvement of cancer care via artificial intelligence

    Debra Patt MD, expounds on the improvement of cancer care via artificial intelligence

    Dana Chase, MD, shares details about PRIMA and PAOLA clinical studies regarding ovarian cancer

    Dana Chase, MD, shares details about PRIMA and PAOLA clinical studies regarding ovarian cancer

    Geoffrey Oxnard, MD, explains how genomic markers can guide treatment in PD-L1 positive NSCLC

    Geoffrey Oxnard, MD, explains how genomic markers can guide treatment in PD-L1 positive NSCLC

    Brad Prechtl tells how his practice is working to improve cancer care

    Brad Prechtl tells how his practice is working to improve cancer care